Prophylaxis of cytomegalovirus disease in high-risk patients

CMV disease is an important peristent factor for enhanced morbidity and mortality in immunocompromised patients. In high-risk patients the prevention of primary infection or reactivation of latent infection is endeavoured by means of various antiviral strategies. However, the prevention of CMV disease by immunomodulators appears to be a hopeful additional tool for the treatment of immunocompromised patients and ought to be further investigated.